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Summary A variant form of the human oestrogen receptor (ER) mRNA lacking sequences encoded within exon 5 has been described
(Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malloy BW, McGuire WL 1991, Cancer Res 51:
105-109).We have examined the expression of the exon 5-deleted ER (HEA5) mRNA variant in breast biopsies using reverse transcriptase
polymerase chain reaction (RT - PCR). HEA5 mRNA was present in only 13% of non-malignant breast tissues compared with 32% of
carcinomas (95% Cl, P=0.05). Presence of the HEA5 mRNA was associated with the presence of immunohistochemically detected ER
(P=0.015) and progesterone receptor (PR) (P=0.02). There was a positive correlation between the presence of HEA5 and disease-free
survival (P=0.05), suggesting that the presence of HEA5 may be an indicator of better prognosis. We have raised a monoclonal antibody
specific to the C-terminal amino acids of HEA5. This antibody recognized the variant but not the wild-type ER protein. We show that HEA5
protein is present in breast cancer using immunohistochemical techniques. We also analysed trans-activation by HEA5 in mammalian cells
and showed that, in MCF-7 cells, HEA5 competes with wild-type ER to inhibit ERE-dependent trans-activation. Our results indicate that this
variant is unlikely to be responsible for endocrine resistance of breast cancer, but its presence at both the mRNA and protein level suggest
that it may, nevertheless, be involved in regulating the expression of oestrogen-responsive genes in breast cancer.
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Two-thirds of human breast carcinomas are characterized by the
presence ofappreciable amounts ofoestrogen receptor (ER)protein.
A proportion of these tumours also contain progesterone receptor
(PR) and it is generally accepted that ER regulates PR gene expres-
sion. The presence of ER is correlated with a better prognosis and
ER+/PR+ tumours are much more likely to respond to endocrine
therapy than ER-/PR- tumours. Interestingly, ER-/PR+ tumours are
twice as likely torespond as ER+/PR- tumours. A significantpropor-
tion of ER+/PR+ tumours, however, fail to respond to endocrine
therapy and those that do so eventually become resistant to such
therapy. The mechanisms leading toendocrine resistance are not yet
clear (for reviews see McGuire, 1978; McGuire et al, 1991; Fuqua,
1994; Horwitz, 1994; Sluyser, 1994).
The human oestrogen receptor cDNA (Green et al 1986) and its
gene (Ponglikitmongkol etal, 1988) havebeencloned andthe mole-
cular mechanisms by which it acts are well understood. Alignment
of the predicted ER amino acid sequences from different species
shows that it can be divided into six regions A to F on the basis of
differing amino acid sequence homology (Krust et al, 1986).
Functional studies have shown that region C encodes the DNA-
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binding domain (DBD) and region Econtains the hormone-binding
domain (HBD) (Green and Chambon, 1987; Kumar et al, 1987).
Regions A/B and E contain trans-activation functions 1 (AFI) and
2 (AF-2) respectively (Kumar et al, 1986, 1987; Webster et al,
1988; Lees et al, 1989; Tora et al, 1989a; Berry et al, 1990). Recent
studies indicate that region F plays a role in modulating transcrip-
tional activation by ER (Montano et al, 1995).
There is little evidence for gross rearrangements of the ER gene
in breast carcinomas. However, we previously reported the pre-
sence ofmultiple mRNA species in breast carcinomas (Barrett-Lee
et al, 1987), and since then several groups have described the pres-
ence of mutant or variant forms of ER. Restriction enzyme poly-
morphisms and point mutations have been described. A point
mutation leading to a single amino acid substitution in region B has
been implicated in increased incidence of spontaneous abortions
(Lehreretal, 1990, 1992), althoughthe mechanism ofactionofthis
mutant is unclear. A recent report describes a point mutation at
codon 157 (region B) leading to a premature stop codon (Smith et
al, 1994). In breast cancer, however, there have been no reported
mutations leading to altered ERprotein. A number ofrecent studies
have demonstrated the presence ofER splice variants lackingexons
2, 3, 4, 5 or 7 in breast cancer and/or in breast cancer-derived cell
lines. Other variants containing intronic sequences have also been
described. Most of these variants would be expected to behave as
dominant-negative effectors of wild-type ER (McGuire, 1978;
Murphy, 1990; Fuqua et al, 1991; McGuire et al, 1991; Wang and
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Miksicek, 1991; Dotzlaw et al, 1992; Fuqua et al, 1992; Fuqua,
1994; Horwitz, 1994; Sluyser, 1994).
Fuqua et al (1991) identified an exon 5-deleted variant (HEA5)
in ER-/PR+ breast carcinomas that would encode a truncated
(40 kDa) polypeptide lacking most of the HBD. This variant acti-
vated an oestrogen response element(ERE)-containing reporter gene
in a yeast expression system at a low level (10-15%) compared with
wild-type ER, in the absence ofoestrogen. Ithas been suggested that
this variant may be responsible for resistance to tamoxifen, since it
lacks most ofthe HBD and could be constitutively active.
Despite a considerable number of studies describing the pres-
ence of variant forms of ER mRNA in breast cancer, in menin-
giomas, the uterus and in cell lines, the presence ofvariant proteins
has not been clearly demonstrated. However, immunoblotting and
gel retardation studies have suggested that multiple ER polypep-
tide species are present in some breast tumours, and there are indi-
cations that some of these species exhibit abnormal properties,
such as altered subcellular distribution (for reviews and references
see Murphy, 1990; Foster et al, 1991; Scott et al, 1991). These
forms of the ER protein could arise as a result of mutations in the
ER gene or they may be specific exon-deleted variants ofthe ER.
In this study, we have used semi-quantitative polymerase chain
reaction (PCR) to examine the expression of the exon 5-deleted
ER mRNA in carcinomas and non-malignant breast biopsies and
correlated its presence to clinical features of this patient group to
determine whether expression ofthis varianthas abearing on clin-
ical outcome. To address the question of whether HEA5 protein
exists in vivo, we raised a monoclonal antibody that is specific for
HEA5 and used this for immunohistochemical studies. We have,
furthermore, analysed the action ofHEA5 in the mammalian COS-1
and HeLa cell lines and in the human breast cancercell line MCF-7
using transient transfection assays to determine whether its
activity could lead to endocrine resistance.
MATERIALS AND METHODS
Tissue samples
Tissue was obtained from 154 patients undergoing surgery at
St George's Hospital or the Royal Marsden Hospital in London
between 1976 and 1990. Clinical and pathological characteristics
are shown in Table 1. Patients were either treated by mastectomy
(n=113) or wide local excision (n=41). Adjuvant tamoxifen was
given to 80 of these patients. Only five patients received adjuvant
chemotherapy and 69 received no systemic adjuvant treatment.
Table 1 Relationship between wild-type and variant ER mRNA and clinical
features
Clinical parameter Significance of associations (P.values)a
WT-f-actin HEA5-WT
Age NSb NS
ER 0.005 0.015
PR NS 0.02
Tumour size NS NS
Nodal status NS NS
Histology NS NS
Menopausal status NS NS
aLog rank test: hazard ratio (95% Cl) (P-value) given. bNS, not significant at
95% Cl.
The mean follow-up time was 61.2 months. A total of 23 non-
malignant breast biopsies were also collected and these included
three biopsies from breast samples adjacent to cancerbuthistolog-
ically normal, seven biopsies representing benign breast disease
and 13 normal breast tissues from reduction mammoplasty speci-
mens. All samples were snap frozen and stored in liquid nitrogen
immediately after removal.
Steroid receptor determination
Paraffin sections of all malignant biopsies were analysed for ER
and PR content immunohistochemically using the specific mono-
clonal antibodies, lD5 (Dako Ltd, UK) according to Sannino and
Shousha (1994) and PR-ICA (Abbott Laboratories, UK) (Burgess
and Shousha, 1993) respectively, except in 15 cases for which
sufficient tissue was available only for ER determination.
Isolation of RNA
Total cellular RNA was isolated from frozen tissue samples using
the guanidinium isothiocyanate method (Sambrook et al, 1989),
quantitated spectrophotometrically, analysed on 1% agarose gels in
standard Tris acetate-EDTA buffer and stored at-70°C in water.
Oligonucleotide primers
Oligonucleotides were synthesized on an Applied Biosystems
DNA synthesizer using phosporamidite chemistry, deprotected
with ammonium hydroxide for 5-6 h at 55°C, vacuum dried,
resuspended in water and used without further purification. These
were supplied by the Advanced Biotechnology Centre at Charing
Cross Hospital, London. The sequences of the ER oligos were
5'-GGAGACATGAGAGCTGCCAAC-3' and 5'-CCAGCAGCA-
TGTCGAAGATC-3' (Fuqua et al, 1991). The 0-actin primers
had sequences 5'-CATCTCTTGCTCGAAGAAGTCCA-3' and
5'-ATCATGTTTGAGACCTTCAA-3' (Bansal et al, 1995).
Reverse transcription and polymerase chain reaction
amplification
RNA (4 ,ug) was converted into cDNA using MMLV reverse tran-
scriptase (RT), as described previously (Bansal et al, 1995). PCR
conditions were optimized by varying the amount of RT product
input, the number of cycles and magnesium chloride concentra-
tion. The optimal conditions are described: 100 ng of RT product
was added to 100 ,l of PCR mixture containing 67 mm Tris-HCl,
pH 8.8, 16.6 mm ammonium sulphate, 1.5 mm magnesium chlo-
ride, 0.45% Triton X-100, 0.2 mg ml-' gelatin, 200 gM dNTP, 1
unit of Taq polymerase (Peninsula, UK) and 250 ng ofeach ofthe
two ER primers and the two P-actin primers. The samples were
overlaid with mineral oil and subjected to 25 cycles of amplifica-
tion with denaturation at 94°C for 1 min, annealing at 580C for 1
min, extension at 72°C for 2 min and a final extension at 72°C at
the completion of25 cycles for 10 min.
Analysis of PCR products
PCR products were extracted with chloroform and 10-gl aliquots
were electrophoresed on 2% agarose gels in Tris acetate-EDTA
buffercontaining ethidiumbromide. DNA was blottedonto Hybond
N+ membrane (Amersham) using 0.4 N sodium hydroxide and
hybridized according to the Amersham protocol, using either
random primer-labelled ER cDNA (HEGO; Tora et al, 1989b) orthe
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,-actin cDNA (Bansal et al, 1995). Blots were exposed to Kodak
XR-OMAT film using intensifying screens for 1-24 h and band
intensities were quantified using a Shimadzu laserdensitometer.
Band intensities were normalized between blots by inclusion of
a reference sample on each blot, which served to correct for varia-
tions in amplification, blotting, hybridization and autoradiographic
exposure times. To estimate the amount of wild-type ER mRNA,
the normalized densitometric value ofthe 419-bp band was divided
by the normalized value ofthe 0-actin signal for each sample. The
amount ofvariant ER was expressed as a ratio ofthe densitometric
values ofthe 300-bp variant band to the 419-bp wild-type ER band.
Statistical analyses
Wild-type ER-actin and variant - wild-type ER ratios were
compared between groups using the non-parametric Mann-Whitney
test in which the ratios were compared between two groups (ER,
PR, menopausal status), and the Kruskal-Wallis test was employed
ifmore than two groups were being compared (histological type and
grade). Spearman rank correlation was used to examine the relation-
ship with age, tumour size and nodal status.
The Kaplan-Meier method was used to construct life-tables and
the log rank test was employed to compare life-table curves.
Multivariate analysis was carried out using forward stepwise
selection with the Cox proportional hazards model.
Preparation of antigen and immunizations
A peptide with the sequence GTRENV, corresponding to the
predicted C-terminal amino acid sequence ofthe HEA5 polypeptide,
was synthesized on a Wang resin (Calbiochem, UK) using an
Abimed AMS 422 Multiple Peptide Synthesizer and Fmoc method
(Atherton and Sheppard, 1985). Before completion ofthe synthesis,
a cysteine was added to the N terminus to facilitate subsequent
coupling to a carrierprotein. The peptide was cleaved from the resin
according to King et al (1990); reverse-phase high-performance
liquid chromatography (HPLC) and mass spectrometry were
performed to check purity. A sample of 10 mg of the peptide was
coupled to 10mg ofpurified protein derivative oftuberculin (Central
Veterinary Laboratories, UK) (Morrison et al, 1987) using the heter-
obifunctional agent mal-sac-HNSA (Bachem Feienchemikalen AG,
Switzerland) (Aldwin and Nitecki, 1987). The final conjugate was
diluted to 20 ml with sterile physiological saline.
Female Balb/c mice were primed subcutaneously with one dose
of BCG vaccine (Glaxo, UK) (Lachmann et al, 1986). Mice were
then immunized three times subcutaneously at monthly intervals
with 200gl ofan emulsion ofpeptide/tuberculin conjugate (50 jig
ofpeptide per immunization). The sera were screened as described
below. The highestresponding animal was selected andboosted on
three consecutive days before fusion with an intravenous injection
of200-300gl ofpeptide/tuberculin conjugate.
Enzyme-linked immunosorbent assay (ELISA)
screening
The peptide GTRENV was synthesized, then biotinylated using a
long-chain biotin ester (NHS-LC-Biotin; Calbiochem, UK). Dry
peptidyl resin (0.1 g) was suspended in 1 ml of N, N-dimethyl-
formamide (DMF; Rathbum Chemical Co., UK) and 35 mg of
long-chain biotin estertogether with 13.5 mg of 1-hydroxybenzotri-
azole (Sigma, UK) added. The mixture was incubated ovemight at
room temperature and washed thoroughly with DMF and ether and
dried. Biotinylation was checked using a ninhydrin test (Dupont).
The peptide was cleaved from the resin as above. The polyclonal
antisera from the mice were assayed by ELISA (Harlow and Lane,
1988) using streptavidin microtitre plates (Actiplate S plates;
Bioproducts, UK) according to manufacturers' protocols, except
that a Tris buffer (0.15 M sodium chloride/25 mm Tris-HCl, pH7.2)
was used instead ofphosphate-buffered saline (PBS).
Preparation of hybridomas and ascites
The spleen was removed aseptically and the splenocytes fused
with Sp2/o myeloma cells (Celltech, UK) as described previously
(Galfre and Milstein, 1987). After 7 days, the hybridoma super-
natants were screened by ELISA using streptavidin plates as
described above. The strongly reacting antibodies were identified
and a selection of hybridomas transferred for expansion.
Supematants from the latter were titrated by ELISA and the
strongly reacting supematants were tested on frozen breast tissue
sections by immunoblotting and by Westem blotting (as below).
The most promising hybridoma was recloned in methyl cellulose
(McCullough and Spier, 1990) and the supematants were re-evalu-
ated for antibody specificity by ELISA, immunoblotting, gel shift
and immunohistochemistry. Subclass and antibody concentrations
were determined according to manufacturer's protocols (Binding
Site, UK). Thehybridomacell line was expanded to approximately
2 x 10 cells. The cells were suspended in 10 ml ofIMDM (Gibco,
UK). Female Balb/c mice, previously primed with an intraperi-
toneal injection of0.3 ml ofFreund's incomplete adjuvant (Gibco,
UK), were then injected intraperitoneally with 0.5 ml of the
suspension. The mice were sacrificed and the ascitic fluid drained
5-7 days later. The ascitic fluid was purified using a protein A
column (Bioprocessing UK).
Transfection assays
The mammalian expression vectorpSG5 was used forexpression of
wild-type ER (HEGO) and HE15 (amino acids 1-281 ofhuman ER)
and have been describedpreviously (Toraetal, 1989a,b). HEA5 was
constructed by site-directed mutagenesis of HEGO (Tora et al,
1989b), using an oligonucleotide with the sequence 5'-AAGAG-
GGTGCCAGGAACCAGGGAAAATG-3'. Positive clones were
identified by loss ofXbaI and NcoI restriction sites and confirmed
using dideoxy sequencing (Sambrook et al, 1989). The reporter
plasmid, 17M-ERE-globin-CAT, and the expression vectors, GAL-
ER(HBD), have been describedpreviously (Webster et al, 1988).
COS-1, HeLa and MCF-7 cells were maintained as described
previously (All et al, 1993a), split into 9-cm plates in Dulbecco's
modified Eagle medium (DMEM)-phenol red with 5% double char-
coal-stripped FCS and transfected using the calcium phosphate tech-
nique (Toraetal, 1989b).COS-1 andHeLacells weretransfectedwith
2 jig of 17M-ERE-globin-CAT along with 0.5 jg ofthe0-galactosi-
dase reference plasmid, pCHI10 (Pharmacia, UK), 0.5 jig of pSG5,
HEGO, HE15 orHEA5 expressionplasmids, togetherwith Bluescribe
M13+ DNA (BSM+; Stratagene, UK) as carrier DNA to make a total
of20 jig ofDNA. MCF-7 cells were transfected with 2.0jig of 17M-
ERE-globin-CAT and 4jg of pCH1O0. Varying amounts of HEAS
DNA together with pSG5, to a total of5 jig, and 9 jig ofBSM+ to a
total of 20 jig of DNA, were used. Oestrogen, hydroxytamoxifen or
ICI 164, 384wereaddedas appropriate, cells wereharvestedandCAT
assays wereperformed as described (Ali et al, 1993a).
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Immunoblotting, gel shifts and immunocytochemistry
COS-1 cells were transfected with 5 ,ug ofpSG5 or HEGO or 10 jig
ofHEA5, together with human placental DNA (Sigma, UK) to atotal
of 20 jig for immunoblotting, gel shifts and immunocytochemistry,
as above. Whole cell extracts were prepared from confluent 9-cm
plates of transfected pSG5-, HEGO- and HEA5-transfected COS-1
cells for immunoblotting and gel shift assays. Cells were washed
with chilled phosphate-buffered saline (PBS), scraped, collected in
PBS, centrifuged at 1000 g for 5 min at 4°C, and cell pellets were
resuspended in 100,ul of20 ml Tris-HCl, pH7.5, 400 mm potassium
chloride, 2 mm dithiothreitol, 1 mm EDTA, 20% glycerol, 0.5 mM
phenylmethylsulphonyl fluoride (PMSE) and 0.5 jig ml-' leupeptin,
aprotinin, pepstatin, antitrypsin and chymostatin. After three
cycles of freeze-thaw (-80°C/0°C), the samples were centrifuged at
15 000 g for 20 min at 4°C and stored at-80°C until required.
COS-l extracts (10 jig) were resolved on 10% sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting was performed essentially as described (Ali et al,
1993b). The ER monoclonal antibody, BlO (Ali et al, 1993b),
was used at 0.5 jig ml-' and aHEA5 was used at 2 jg ml-' for
immunoblotting. Alkaline phosphatase-labelled rabbit anti-mouse
IgG was used as the second antibody and visualisation was carried
out using BCIP and NBT substrates as indicated in the manufac-
turer's protocol (Promega, UK).
Gel shift assays were performed using 5 jig of the COS-1
extracts as described (Ali et al, 1993b). For 'supershifts' 1-2 jg of
B 10, F3 and xHEA5 were added to the gel shift mix.
For immunocytochemistry, COS-1 cells were grown on glass
coverslips in 9-cm dishes. Transfections were performed as above.
Cells were fixed in 3.7% formaldehyde-PBS for 10 min, washed
with PBS for 5 min, placed in methanol for 3 min at -20°C, cold
acetone for 1 min at -20°C and washed twice with PBS for 5 min.
The coverslips were incubated in 10% goat serum in PBS for
15 min to block non-specific binding. Primary antibody (at 0.5 jig
ml-') was added and incubation carried out for 1 h at room tempera-
ture followed by two washes in PBS for5 min. The second antibody
(goat anti-mouse IgG; Sigma, UK) was used at 1:25 dilution in PBS
for 20 min at room temperature, followed by two washes in PBS.
Horseradish peroxidase-labelled mouse anti-goat IgG (Promega,
UK) was used in the third incubation at room temperature for
20 min at a dilution of 1:50 in PBS. The coverslips were washed
twice in PBS and DAB substrate/reagent (Abbott, UK) was added
for 10 min. The coverslips were washed in gently running water for
5 min, counterstained in 1% Harris's haemotoxylin for 5 min and
placed twice for 2 min in 95% ethanol, 100% ethanol, then in
xylene and mounted on slides coated with a drop ofDPX mountant.
Paraffin sections were immunostained as described (Sannino
and Shousha, 1994), using the ID5 (Dako, UK) and aHEA5 anti-
bodies diluted to 0.5 jig ml-'.
RESULTS
PCR analysis of the exon 5 variant in tumour tissue and
in normal breast
Oligonucleotides encoding sequences lying within exons 3/4 and 6
of the human ER gene (see Figure IA) (Ponglikitmongkol et al,
1988) were used to amplify total RNA isolated from 154 breast
cancers and 23 non-malignant breast tissues. PCR conditions were
optimized such that measurements were made during the linear
phase of amplification for both ER and 3-actin (data not shown).
In cases in which high input led to product saturation, measure-
ments were repeated using diluted sample. Figure 1B illustrates
some of the results. A predominant band corresponding to wild-
type ER (419 bp) was seen in PCR products from non-malignant
breast samples (lanes 5 and 6). Identity was confirmed by diges-
tion ofthe product with HindIII, which produced two fragments of
about 160 bp and 270 bp as predicted from the hER cDNA
sequence (Green et al, 1986) (data not shown). The PCR products
derived from cancer tissue RNA also showed this 419-bpfragment
but in about a third ofthe cases we also observed a smaller 300-bp
fragment (Figure 1, lanes 3 and 4), corresponding to the fragment
lacking exon 5 sequences described previously (Fuqua et al, 1991).
Cloning and sequencing of the two PCR products confirmed the
identities of the 419-bp and 300-bp products as wild-type ER and
the exon 5-deleted variant respectively (data not shown).
The amount of ER mRNA was determined as a ratio relative to
the P-actin levels. None of the tumours were altogether negative
for ER transcripts, including those which were ER negative
immunohistochemically. Levels of ER-p-actin varied between
samples and, in order to determine whether ER transcript levels
were proportional to ER protein levels, we compared ER-1-actin
ratios with ER status, as determined immunohistochemically.
There was a good correlation using the log rank test at 95% CI,
with P=0.005 (Table 1), indicating that using these PCR conditions
the signals obtained reflect real ER mRNA levels in the samples.
Expression of the HEA5 variant was found in only 3/23 (13%)
non-malignant breast tissues, compared with 50/154 (32%) cancers
(P=0.05). Altogether 44% of ER+/PR+ cancers contained HEA5,
compared with only 15% of ER-/PR- cancers. The proportion of
ER+/PR- and ER-/PR+ cancers expressing HEA5 was not signifi-
cantly different fromtheER-/PR+ group (32% and 29% respectively)
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Figure 1 The exon 5-deleted oestrogen receptor variant in breast cancer. A
shows a schematic of the oestrogen receptor mRNA with the positions of
exons 1-8 marked. Also shown is the position of the primers used to amplify
a region including exon 5. The primer sequences are given in Materials and
methods. The predicted amino acid sequence is shown for wild-type ER and
the variant (HEA5) together with the position of regions A-F. The five amino
acids at the C-terminus of HEA5 that arise owing to a frameshift are shown in
the single letter amino acid code. The asterisk denotes the stop codon
leading to premature termination and a truncated polypeptide. B shows the
PCR products obtained for two breast carcinomas that contain HEA5 and two
that do not and two normal breast samples. The upper band is the 419-bp
product obtained from wild-type mRNA and the lower band (lanes 3 and 4) is
the 300-bp variant band. The PCR was performed using 100 ng of RT cDNA
and 25 cycles of amplification, as described in Materials and methods
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Table 2 Expression of HEA5 in tumours in relation to hormone receptor
status
ER/PR HEA5-positive HEA5-negative Totala Percentageb
+I+ 25 32 57 44
+/- 11 23 34 32
-/+ 2 5 7 29
-/- 6 35 41 15
Total 44 (6) 95 (8) 139 (154) 32 (32)
ER and PR status were determined immunohistochemically as described in
the text and in Materials and methods. aPR status was not available for a
further 15 tumours; these are included in the figures in brackets. bPercentage
of tumours positive for HEA5 in each class.
(Table 2). The amount ofthe HEA5 product relative to wild-type ER
within each sample ranged from 0% to 30% (data not shown). The
presence ofthe HEA5 variant was related to both ER (P=0.015) and
PR (P=0.02) status, as determined byimmunostaining(Table 1). The
presence and absence of HEA5 was compared with clinical features
in Table 3. There were no apparent correlations between any of the
clinical features examined and the presence or absence of HEA5,
with the exception of menopausal status; 21/51 (41%) of pre-
menopausal patients being HEA5 positive compared with 29/74
(28%) ofpost-menopausal patients (but see below).
Correlation between HEA5 levels and clinical
parameters
Univariate and multivariate analyses were used to correlate disease-
free and overall survival with the presence or absence of HEA5
(Tables 4 and 5), compared with other clinical parameters. Using
univariateanalysis, disease-free and overall survival were notfound
to be correlated with the age of the patient at the time of diagnosis,
or with the menopausal status. There was no correlation with histo-
logical features ofthe cancers, butpatients with ER-positive cancers
did significantly betterthan those with ER-negative cancers forboth
disease-free and overall survival. PR+ patients also showed better
overall survival. As expected, clinical and pathological tumour size
and nodal status were related to prognosis (Table 4). Interestingly,
patients whose tumours contained HEA5 appeared to have margin-
ally better disease-free survival than those who did not have any
HEA5 (P=0.05). The presence of HEA5 was also associated with
increased overall survival, but this failed to reach statistical
significance (P=0.09). Multivariate survival analysis showed that
ER and tumour size were significant independent predictors of
disease-free and overall survival; clinical nodal status was found to
be significant for disease-free but not overall survival; HEA5 was
not found to be a statistically significant independent predictor of
either disease-free or overall survival. Figure 2 shows survival
curves for HEA5-positive (n=50) and HEA5-negative (n=104)
patients, illustrating a clear trend towards a survival advantage for
HEA5-positive patients for both disease-free and overall survival.
Preparation of exon 5-deleted ER-specific monoclonal
antibodies
Deletion of sequences encoded within exon 5 of the human
oestrogen receptor gene leads to the splicing of exon 4 to exon 6,
resulting in a frameshift and the introduction of five new amino
acids followed by a stop codon (Figure IA). Translation of the
Table 3 Clinical features of patients with respect to HEA5 expression
HEA5-positive HEA5-negative
Age (years)a
Range 39-90 26-85
Mean 56.9 59.4
Menopausal status
Premenopausal 21 (42%) 30 (29%)
Post-menopausal 29 (58%) 74 (71%)
Total 50 104
Tumour sizeb
T1-T2 32 (82%) 63 (77%)
T3-T4 7 19
Not knownc 11 22
Total 50 104
Nodal status
Positive 14 (37%) 37 (42%)
Negative 24 (63%) 50 (58%)
Not knownd 12 17
Total 50 104
Histology
Invasive ductal 46 (92%) 95 (91%)
Invasive lobular 2 (4%) 5 (5%)
DCIS 0 1 (1%)
LCIS 0 0
Others 2 (4%) 3 (3%)
Total 50 104
Fifty cancers were HEA5 positive and 104 were HEA5 negative. Figures in
brackets are percentages calculated using only the known values. aFollow-up
(mean): 61.2 months. bTumour size was assessed clinically according to
TNM staging (UICC Handbook). cNot accurately assessed clinically. dAxilla
not dissected.
Table 4 Univariate survival analysisa
Disease-free Overall
survival survival
Age (<50 years vs > 50 years) NSb NS
ER Negative 1.00 1.00
Positive 0.61a (0.39-0.96) 0.46 (0.27-0.78)
P=0.03 P=0.003
PR Negative 1.00 1.00
Positive 0.73 (0.50-1.06) 0.60 (0.37-0.95)
P=0.09 P=0.03
VWT ratio 0 1.00 1.00
>0 0.62 (0.38-1.01) 0.60 (0.33-1.08)
P=0.05 P=0.09
Tumour size (T stage) Trend (P<0.001) Trend (P<0.001)
Nodal status (0, la, lb) Trend (P<0.001) Trend (P<0.001)
Histology NS NS
Menopausal status (pre/peri-post) NS NS
aLog rank test: hazard ratio (95% Cl) (P-value) given. bNS, not significant at
95% Cl. cER-positive patients are only 61% as likely to experience an event
as ER-negative patients at any time point during follow-up.
HEA5 mRNA would, therefore, be expected to yield a polypeptide
of about 40 kDa. We synthesized a peptide with the sequence
GTRENV, corresponding to the final six C-terminal amino acids of
HEA5 and containing a cysteine at the N terminus for coupling to
tuberculin for immunization of mice. The peptide was immuno-
genic in mice as determined by ELISA and immunoblotting of
HEA5-transfected COS-1 cell extracts (data not shown). After cell
fusion, supernatants from 29 cultures were tested by ELISA, by
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Table 5 Multivariate survival analysisa
Disease-free Overall
survival survival
Age (<50 years vs .50 years) NSb NS
ER Negative 1.00 1.00
Positive 0.55C (0.33-0.93) 0.35 (0.19-0.65)
P=0.03 P=0.001
PR Negative 1.00 1.00
Positive 0.93 (0.57-1.51) 0.68 (0.36-1.26)
P=0.75 P=0.21
V:WT 0 1.00 1.00
>0 0.66 (0.37-1.19) 0.58 (0.28-1.18)
P=0.16 P=0.12
Tumour sized Ti 1.00 1.00
T2 1.57 1.73
T3 2.46 2.98
T4 3.85 5.14
P=0.002 P<0.001
Nodal status 1.52 (1.05-2.2) NS
(positive vs negative) P=0.03
Histology NS NS
Menopausal status NS NS
(pre/peri-post)
aPerformed using Cox's regression allowing for tumour size and nodal status:
hazard ratio (95% Cl) (P-value) given. bNS, not significant at 95% Cl. cER-
positive patients are only 55% as likely to experience an event as ER-
negative patients at any time point during follow-up. dTumour size was
assessed clinically according to TNM staging (UICC Handbook).
immunoblotting and immunocytochemistry of HEA5-transfected
COS-1 cells. A single hybridoma was selected, based on the inten-
sity and specificity ofthe reactions obtained in these tests (data not
shown; and see below) and identified as IgG2b. It was further
amplified, culture supernatants were collected and ascites fluid
was produced, and is hereafter referred to as aHEA5.
Detection of HEA5 protein by the aHEA5 monoclonal
antibody in transiently tranfected cells
COS-I cells were transiently transfected with the plasmid pSG5 or
with pSG5 containing either HEGO or HEA5. Cell extracts were
prepared and the xHEA5 monoclonal antibody was tested for
specificity by immunoblotting. The monoclonal antibody, B10,
raised against aminoacids 150-165 (region B) of the human
oestrogen receptor (Ali et al, 1993b) was used forcomparison with
aHEA5. Figure 3A shows that B10 recognized both the wild-type
ER (HEGO, lane 2) and a band at about40 kDa, consistent with the
size expected for the HEA5 polypeptide (lane 3). aHEA5 did not
recognize HEGO but did react with the 40-kDa HEA5 polypeptide
(compare lanes 2 and 3 with lanes 5 and 6).
The DNA binding of ER to an oestrogen response element
(ERE) can be determined in vitro using the gel shift assay by incu-
bating cell extracts containing ER with radioactively labelled
ERE-containing oligonucleotides and then resolving the ER-ERE
complex using non-denaturing polyacrylamide gel electrophoresis
(Ali et al, 1993b). This assay also showed that aHEA5 recognizes
HEA5 but does not recognize the wild-type hER (HEGO). Whole
cell extracts (WCE) of transfected COS-1 cells expressing pSG5,
HEGO or HEA5 were incubated with 32P-labelled oligonucleotides
containing an ERE. WCE of COS-1 cells transfected with the
parent vector pSG5 gave no binding to the ERE (Figure 3B, lanes
1, 4, 7 and 10), in contrast to HEGO-transfected COS-1 cells,
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Figure 2 Disease-free and overall survival curves for patients with variant-
negative (V:WT = 0) and variant-positive (V:WT> 0) breast carcinomas.
A shows disease-free survival for the two groups (n=97 forvariant-negative
and rn47 forvariant-positive patients) Variant (HEA5)-positive patients had
better disease-free survival (P=0.05). B shows that these patients also had
better overall survival with P=0.09 (not significant). The vertical lines show
the confidence intervals and the numbers at risk are shown
which displayed a prominent retarded band (lane 5). HEA5-trans-
fected COS-1 cell extracts also gave a retarded band that migrated
slightly faster than the HEGO complex (compare lanes 5 and 6).
Note that the HEA5-ERE complex was much weaker than the
HEGO-ERE complex, despite similar levels ofeach protein being
present in the extracts as judged by immunoblotting (data not
shown; and see Figure 3A, compare lanes 2 and 3).
Addition of the F3 monoclonal antibody, which recognizes
amino acids 578-595 ofhER (Ali et al, 1993b), 'supershifted' the
HEGO-ERE complex owing to the formation of a large anti-
body-ER-ERE complex (compare lanes 2 and 5). The HEA5
complex was not supershifted because of the absence of amino
acids 578-595 (lane 3). B1O supershifted both HEGO and HEA5
(lanes 8 and 9), as expected. aHEA5 did not supershift HEGO
(lane 11) but did give slower migration ofHEA5 (lane 12), further
showing that aHEA5 recognizes HEA5, but not wild-type, ER.
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Figure 3 Immunoblot gel shift and immunocytochemical analysis bf COS-1
cells transfected with ER and HEAM using Bl0 and aHEA5 monoclonal
antibodies. (A) Lanes 1-3 and 4-6 were immunoprobed with Bl0 and
aoHEA5 respectively. The positions ofthe molecularweightstandards are
indicated in kDa. B shows gel-shiftanalysis of pSG5-, HEGO- and HEA5-
transfected COS-1 cell extracts, in the presence ofcontrol antibody (lanes
4-6), F3 (lanes 1-3), Bl0 (lanes 7-9) oraHEAS (lanes 10-12). (C) COS-1
cells transfected with pSG5, HEGO or HEAS were fixed and incubated with
either mouse IgG (control), B10 or aHEAS. Counterstaining was performed
with haematoxylin
HEA5 + -
IgG
F3
B10
aHlEA5
+ +
m mm
_ _ m
2 3 4 5 6 7 8 9 10 11
+ COS-1 cells were grown on coverslips, transfected with pSG5,
HEGO or HEAM using the calcium phosphate method, fixed and
immunostained using mouse IgG, B10 and acEA5 antibodies.
Figure 3C shows that no staining was observed with pSG5-trans-
- fected cells. Both HEGO- and HEA5-transfected COS-1 cells
showed aproportion ofcells with strong nuclear staining. Staining
with aHEA5 gave nuclearstaining only in COS-1 cellstransfected
+ with HEA5.
Expression of HEA5 protein In breast carcinomas
The above transfection studies showed that aHEA5 can specifi-
cally recognize the HEA5 polypeptide in immunoblotting, gel shift
and immunostaining assays. We next examined breast cancer
samples for the presence of HEA5 protein. Twenty samples were
chosen on the basis of high and low levels of HEA5 mRNA, as
determined by PCR (above). Extracts were prepared from tissue
stored in liquid nitrogen by homogenization, followed by
freeze-thawing (-80°C/0°C) and centrifugation at 15 000 g for
removal of insoluble material. The lysates were analysed by
immunoblotting andgel shift assays. We found no evidence forthe
presence ofthe HEA5 polypeptide (data not shown).
Thereactivity ofaHEA5 was evaluatedbyusing frozen sections,
since immunohistochemistry offers a more sensitive method of
detection than the methods used above. Frozen sections from a
cancer expressing high levels of HEM5 mRNA, as determined by
PCR (a ratio of0.25 variant-wild-type ER; see Figure 1B, lane 3),
were immunostained for the presence of HEA5 protein. Serial
sections were immunostained using the ER monoclonal antibody
iD5 (Dako, UK), which was raised against an epitope in the N-
terminal portion of the ER protein, and therefore would be
12 expected to recognize both the wild-type ER and the HM5
polypeptides. iD5 exhibited strong nuclear staining confined to
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the carcinoma cells (Figure 4A). xHEA5 similarly gave nuclear
staining of malignant cells (Figure 4B), although some cyto-
plasmic staining was also evident. However, the specificity of
aHEA5 was confirmed by immunostaining with mouse IgG and
by competing with the immunizing antigen. Immunostaining with
mouse immunoglobulins gave no staining (Figure 4C).
Preincubation of xHEA5 with the peptide C-GTRENV, used for
immunization, led to loss of staining (Figure 4D), whereas lD5
staining was unchanged (Figure 4E), further indicating that the
HEA5 staining was specific.
In order to demonstrate further the specificity of our antibody,
immunostaining was performed on another cancer positive for ER
A
and for HEA5 mRNA expression and one that showed ER posi-
tivity but HEA5 negativity by PCR. The staining observed for an
ER+/PR+ cancer expressing high levels of HEA5 mRNA
(variant-WT ratio=0.25; see Figure IB, lane 4) is shown in Figure
4F-H. Strong nuclear staining ofthe malignant cells was observed
with the ER antibody lD5 (Figure 4F). aHEA5 also showed
nuclear staining of some malignant cells, as well as cytoplasmic
positivity (Figure 4G). Case 2 gave positive staining for ER (using
ID5; Figure 41) but no nuclear staining was seen with cxHEA5
(Figure 4J). PCR results showed that this sample was negative for
HEA5 mRNA (Figure lB, lane 1). No staining was observed in
any ofthe cases with mouse IgG (Figure 4H and K).
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Transcriptional activation by HEA5 in mammalian cells
We wished to examine HEA5 activity in mammalian cell systems
and used a chloramphenicol acetyl transferase (CAT) gene reporter
system in COS-1 and HeLa cells and in the human breast
cancer-derived cell line MCF-7, which overexpresses ER. HEA5 is
truncated at amino acid 365 in ER and would be expected to act
through AF-1 in a constitutive manner. We compared the trans-
activational ability ofHEA5 with ER (HEGO) and with the in vitro
generated mutant HE15 [containing amino acids 1-281 of ER
(Kumar et al, 1987], which activates transcription through AF-1
(Tora et al, 1989a). The constructs used and the extent ofthe dele-
tions are shown in Figure 5A.
Figure 4 Detection of HEA5 using the aHEA5 antibody and comparison with
an ER antibody on HEA5-positive and -negative breast cancer sections.
Sections of a strongly ER- and HEA5-positive breast cancer sample were
immunostained with 1D5 (A), aHEA5 (B) or mouse igG (C). (D-E) shows the
staining obtained after incubation of alHEA5 (D) or 1D5 (E) with a 100-fold
excess of the immunizing peptide. Another strongly HEA5-positive (F-H)
and a HEA5-negative (I-K) breast cancersample were immunostained
with the ER antibody 1D5 (F and 1), aHEA5 (G and J) or mouse IgG
(H and K). Counterstaining was performed with haematoxylin. Original
magnification x 200
Transfection of HEGO into COS-l cells resulted in a tenfold
increase in transcription in the presence of oestradiol (E2) over its
absence and a 20-fold increase relative to background (Figure 5B);
the trans-activation produced by HEGO in the absence of E2 may
be caused by residual oestrogens in the charcoal-stripped medium
used (Tora et al., 1989b). HE15 activated the CAT gene about 15%
as well as HEGO and showed the same activity in the presence as in
the absence of E2 (Figure SB; and data not shown). HEA5 trans-
activated to levels similar to those obtained with HE15 (FigureSB).
Several studies have shown that AF-1 and AF-2 ofER are sepa-
rable and synergise to give maximal trans-activation by ER (Lees
et al, 1989; Tora et al, 1989a). The synergistic activity ofAF-1 and
AF-2 can be examined using constructs in which AF-2 (region E)
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Figure 5 Comparison of the transcriptional activities of hER, HEl 5 and HEA5 in various cell lines using the 17M-ERE-globin-CAT reporter gene. A shows a
schematic of the human oestrogen receptor gene, together with its exonic structure. Also shown are HEGO, HEA5 and HE15 and the regions present in HEA5
and HEl5 are indicated. B and C show transcriptional stimulation of the reporter gene in COS-1 and HeLa cells, respectively, by the wild-type human ER
(HEGO), the truncated ER mutant HEl5, the exon 5 variant HEA5 or GAL-ER (HBD) in the absence or presence of 10 8M oestradiol (E), 107m 4-
hydroxytamoxifen (0) and 10-7M ICI 164, 384 (I), as indicated. (D) MCF-7 cells were transfected with the ERE-globin-CAT reporter gene with or without
increasing amounts of HEA5, in the presence or absence of E, 0 or 1. Average values of at least three experiments are shown, the level of trans-activation by
HEGO in the presence of E being taken as 100% in each experiment
is fused to the DNA-binding domain of the yeast trans-activator
GAL4 (GAL-ER (HBD)), and using HE1S in which AF-2
sequences have been deleted. When co-transfected together with a
CAT reporter gene containing a GAL4 DNA-binding element
(17M) and an ERE, AF- 1 and AF-2 act synergistically (Webster et
al, 1988; Tora et al, 1989a). In order to examine the mechanisms
of trans-activation by HEAS further and to determine whether it
trans-activates ERE-dependent gene expression in a similar way
to HE1S, i.e. through AF-1, we analysed its ability to synergise
with AF-2 (Figure 5B). GAL-ER activated the 17M/ERE-G-CAT
gene in the presence ofE2. Both HE1S and HEA5 synergised with
GAL-ER to similar extents.
In HeLa cells, AF-1 is unable to activate transcription but can
synergise with AF-2 (Kumar et al, 1987; Lees et al, 1989; Tora et
al, 1989a; Berry et al, 1990). Both HE1S and HEA5 gave very
little trans-activation on their own but synergised with GAL-ER in
the presence of E2 (Figure 5C). These results indicate that HEA5
acts in a similar manner to HE1S, i.e. through AF-1, although as
before 4.0 ,ug of HEA5 needed to be transfected compared with
0.5 ,ug ofHElS for this level ofsynergism.
Tamoxifen (and its metabolite, 4-hydroxy-tamoxifen) is a partial
antagonist of oestrogen, in that it enables trans-activation through
AF-1, while inhibiting the activity ofAF-2 (Berry et al, 1990). ER
trans-activated about 20% as well in the presence of hydroxy-
tamoxifen (0) as in the presence of E2 in COS-1 cells, whereas
little activity was seen in HeLa cells. HE1S and HEA5 also trans-
activated in COS-1 cells but not in HeLa cells. These results are in
broad agreement with those reported previously (Berry et al,
1990). Note also that, in the presence of hydroxy-tamoxifen, little
synergistic activity was observed when GAL-ER and HE1S or
HEAS were co-transfected. As expected, in the presence of the
'pure' antagonist, ICI 164,384, very little ER activity was observed.
In order to examine the effect of HEAS on trans-activation in
the presence of wild-type ER, MCF-7 cells were transfected with
HEAS and the CAT reporter gene. We observed a fivefold induc-
tion by the endogenous ER, on addition ofE2, in cells transfected
with the CAT reporter alone. Co-transfection with increasing
amounts of HEAS inhibited this trans-activation by up to 60%
indicating that HEAS was acting as a 'dominant negative' mutant,
presumably by virtue of its lower trans-activational ability
compared with the wild-type ER. Note, however, that the inhibi-
tion never reached levels obtained with hydroxy-tamoxifen
(Figure SD). An inhibition by HEA5 ofthe low level trans-activa-
tion in the absence of ligand and in the presence of hydroxy-
tamoxifen and ICI 164,384 was also observed and might suggest
that, as in HeLa cells, HEAS cannot trans-activate on its own from
this promoter.
DISCUSSION
The exon 5 deletion variant was first shown to be present at the
mRNA level in ER-/PR+ breast cancers by Fuqua et al (1991), who
showed that it could trans-activate constitutively in a yeast expres-
sion system. We have analysed 154 breast cancers, chosen without
regard to their clinical status, for the presence of HEA5 by PCR.
We have shown that the amount ofwild-type ER product obtained
by this method was strongly correlated with the presence ofER as
determined immunohistochemically (at 95% CI, P=0.005). HEA5
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was present in about 30% ofthe cancers but inonly 10% ofnormal
breast tissue (P=0.05). In breast cancer, the presence ofHEA5 was
related to the presence of ER (at 95% CI, P=0.015) and PR
(P=0.02), in agreement with other data (Daffada et al, 1995).
Prognostic tests using univariate analysis showed that the presence
of HEA5 is associated with longer disease-free survival, although
the results only reach significance to 95% CI with P=0.05.
Multivariate survival analyses showed that the presence of HEA5
is not an independent prognostic factor. These results were unex-
pected in view ofsuggestions that HEA5 could lead to resistance to
endocrine therapy, but concur with the results of Daffada et al
(1995), who showed similar levels ofHEA5 in tamoxifen-resistant
cancers and primary controls.
A number of studies have reported the presence ofER variants at
the mRNA level but none have provided evidence that these
mRNAs are translated. Several studies have found evidence for the
presence ofER-like proteins unable to bind DNA orligand but these
could be proteolytic products ofwild-type ER protein. We therefore
raised a monoclonal antibody that would specifically recognize the
HEA5 polypeptide and present the first evidence for the presence of
HEA5 protein in breast tissues. In an immunohistochemical study,
we have shown that tumours that possess the HEA5 mRNA have
immunostainable HEA5 protein. Although we have demonstrated
the specificity ofourantibodyby artificially overexpressing HEA5
in COS-1 cells, we have not yet been able to demonstrate its pres-
ence in breast cancer using immunoblotting or gel shift assays,
presumably because of low amounts ofendogenous HEA5 protein
and/or its reduced stability. Further studies are underway to
compare the stability ofwild-type and exon 5-deleted ER proteins
using pulse-chase labelling experiments.
We have, furthermore, analysed the trans-activational ability of
HEA5 by transient transfection ofthe ER-negative COS-1 and HeLa
cell lines and in the ER-positive MCF-7 cells. We find that HEA5
can constitutively trans-activate ERE-dependent gene expression in
mammalian cells in addition to the previously described activity in
yeast (Fuqua et al, 1991). HE15, which contains the DBD and AF-1
of the human oestrogen receptor but lacks the HBD/AF-2, has been
well characterized (Kumar et al, 1986, 1987). This construct has
been extensively used to show that AF-l activity is cell- and
promoter-specific (Tora et al, 1989a; Berry et al, 1990; Metzger etal,
1995). Furthermore, the activity ofthe wild-type ER in the presence
of tamoxifen has been correlated to the activity of HE15 by
comparing the cell and promoter specificity of trans-activation by
hER in the presence oftamoxifen, indicating that tamoxifen inhibits
AF-2 but allows activation ofAF-l (Berry et al, 1990). The experi-
ments outlined in Figure 5 indicate that HEA5 behaves mechanisti-
cally like HE15 (amino acids 1-281 of ER), which only contains
AF-1 of ER since: (1) HEA5 can activate a reporter gene in COS-1
cells to similar levels as HE15; but (2) like HE15, HEA5 does not
trans-activate in HeLa cells (see Kumar et al, 1987; Tora et al,
1989a; Berry et al, 1990); (3) HEA5 can synergise with AF-2 (in
GAL-ER) in COS-1; and (4) despite being inactive on its own in
HeLa cells, HE15 is capable of synergising with AF-2 (GAL-ER
(HBD)), as is HEA5. Given our findings that HEA5 shows similar
cell specificity and synergistic properties to HE15, our results indi-
cate that the constitutive trans-activation by HEA5 results entirely
from AF-1 sequences and, since the agonistic activityoftamoxifen is
causedby its activation ofAF-1, while inhibiting AF-2, it is unlikely
that resistance to tamoxifen should arise as a result of the induction
of, or increase in levels of, an ER variant with the same trans-activa-
tional properties as the full-length ER bound by tamoxifen.
Transfection of MCF-7 cells showed that HEA5 inhibits trans-
activation by the endogenous receptor, presumably by competitive
binding on EREs in responsive genes owing to its lowertrans-acti-
vational ability relative to the wild-type receptor. In this respect,
HEA5, despite its ability to trans-activate constitutively, actually
inhibits the action of ER, thereby acting in a manner similar to
some anti-oestrogens, and should not be expected to be respon-
sible for resistance to tamoxifen therapy, as has been suggested
(see Introduction). The analysis of pre- and post-therapy biopsy
samples for changes in the level of the HEA5 variant may shed
more light on this issue. Fuqua (1994) reported that transfection of
HEA5 into MCF-7 cells makes them resistant to tamoxifen. These
results are in apparent contradiction to our results showing that
HEA5 inhibits trans-activation by ER, although we have
performed these studies using chimeric reporter genes. We found
the greatest levels of HEA5 mRNA in PR+ cancers and the lowest
in PR- cancers, regardless ofER status (data not shown). Similarly
a study describing the analysis of 27 breast cancers (Zhang et al,
1993) for the presence ofHEA5 reported highest levels ofHEA5 in
PR+ cancers. In this series only 1/13 ER+/PR+ and 0/3 ER-PR+
cancers failed to express HEA5, whereas 3/7 ER+/PR- and 4/4
ER-/PR- cancers did not express HEA5. Another study (Daffada et
al, 1995) recently showed correlation ofpS2 and PR status and the
presence ofHEA5. Taken together, these results suggest that these
ER-responsive genes might be regulated, at least in part, by HEA5.
The correlation between the presence ofHEA5 and the presence of
PR andpS2 is in agreement with our results indicating better prog-
nosis for HEA5-positive cancers, as these indicators have them-
selves been shown to be correlated with a betterprognosis (Ravdin
et al, 1992; Foekens et al, 1993).
In conclusion, we find that the HEA5 variant is present in a
proportion of breast cancers at the mRNA level and that its pres-
ence does not correlate with a poorprognosis. Its trans-activational
properties suggest that it inhibits trans-activation by wild-type ER,
most likely by direct competition. Our results do, however, support
the notion suggested by others that HEA5 couldplay a role in regu-
lating the expression of certain genes. The detection of the HEA5
polypeptide in breast cancers using a specific antibody is further
indication that HEA5 plays a role in breast cancer.
ADDENDUM
Rea and Parker (1996) recently reported the creation of MCF-7
cell lines stably expressing HEA5 and showed that the variant
stimulated transcription of a reporter gene in chicken embryonal
fibroblasts in the absence of hormone but was only weakly active
in MCF-7 cells. They further showed that the growth-stimulatory
effects ofoestrogen and the growth-inhibitory effects oftamoxifen
were not influenced by the presence of HEA5. These findings are
in general agreement with our results indicating that HEA5 is not
responsible for resistance to endocrine therapy in breast cancer.
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